NGeneBio Announces Massive 80% Dilutive Rights Offering…Severe Equity Dilution and Financial Risk
NGeneBio decided on a large-scale rights offering issuing 7,150,000 new shares, an 80% increase over outstanding shares. The expected proceeds of approximately 22.4 billion KRW will be used for operating funds of 17.3 billion KRW and debt repayment of 5.1 billion KRW, primarily aimed at improving the financial structure rather than growth.
As of Q1 2026, the company faces severe financial distress with accumulated deficits of about 75.8 billion KRW, a debt ratio of 224%, and a current ratio of 48%. A concurrent 3:1 reverse stock split aims to resolve capital erosion, but additional losses could lead to administrative designation or delisting.
The largest shareholder's stake is expected to drop from 21.95% to as low as 17.07% post-offering. Considering outstanding convertible bonds convertible into up to 16.7 million shares and stock options, further dilution and potential management change risks are inherent.
The company has undergone restructuring including DTC business exit, workforce reduction, and a 90% cut in R&D personnel. However, core NGS panel sales remain low, and the US CLIA lab investment has resulted in losses, making the US business uncertain. A significant portion of the raised funds will be used for debt repayment and working capital, focusing on short-term survival.
[AI Summary]NGeneBio's rights offering involves extreme dilution of 80% amidst a precarious financial situation. The majority of proceeds will be used for debt repayment and working capital, focusing on survival rather than growth. Without a swift turnaround to operating profitability, the risk of management designation or delisting remains very high.
KOSDAQ Filing Information
[Correction of Description] Securities Registration Statement (Equity Securities)